Kolling researcher to join Harvard Medical School program Congratulations to Kolling Institute researcher Dr Manasi Mittinty who has been selected for the Advanced Global Clinical Scholar Research training at Harvard Medical School. Manasi is a medical trained researcher with the Pain global scale. Places in the program are highly competitive with only established academics and leaders in their field selected. The program has previously attracted participants from
more than 40 countries in high profile positions such as chief physicians, medical directors, fellows, scientists and medical specialists. Manasi has welcomed the opportunity to join the program. “I feel very excited and privileged to be selected from a global pool of scholars for this training. I look forward to learning from the distinguished faculty at Harvard Medical School,” she said. “This training will help
Kolling Institute researcher Dr Manasi Mittinty
Management and Research Centre and a University of Sydney lecturer. She has a keen interest in translation research and the connections between musculoskeletal conditions, pain science and neuropsychology. The one-year training program provides clinicians and clinician-scientists with advanced training in health care research. One of its key aims is to help participants develop cutting-edge translational research on a world-leading technology, boosting our cancer and neuroscience research capabilities. The Digital Spatial Profiling System has been made possible following a $535,000 grant from the Australian Research Council LIEF scheme. The project is being co-funded by the University of Sydney with a $250,000 contribution, and Macquarie University with a $50,000 commitment. Cancer researcher Professor Mark Molloy has welcomed the establishment of the microscopy system, which has been recognised as one of the most exciting technological advances in the investigation of biological samples globally. “This is wonderful news for our researchers, the Kolling, our partners and ultimately the community of patients we serve,” said the Lawrence
me develop and lead transformative research to promote enhanced wellbeing for people living with arthritis and their families.” Manasi has received several prestigious awards including the Australian Post-graduate award and the Commonwealth funded Endeavour Post-doctoral Research Fellowship, and can now add this opportunity to her list of achievements.
New cutting-edge technology coming to the Kolling The Kolling is set to be one of the first institutes in New South Wales to introduce new Penn Chair of Bowel Cancer Research.
“It will significantly extend our research capabilities and represents an important step towards new treatments. “The digital spatial profiling technology will allow researchers to divide tissues into spatial regions to study how proteins and genes are regulated within parts of the tissues. “Importantly, this will address the limitations of conventional gene and protein profiling methods that produce averaged data which fail to consider the discrete spatial organisation that occurs within tissues. “This will lead to new discoveries around the intricate biological processes that go wrong in diseased tissues, a key step towards finding new drug targets and treatments.”
Cancer researcher Professor Mark Molloy
be used in the study of cancers and neuroscience. This will be extended to include investigators from molecular biosciences, bioengineering, plant biology and bioinformatics. The Kolling’s Executive Director Professor Carolyn Sue and her neuroscience team have welcomed the chance to utilise the new technology in their innovative research projects, especially with their Parkinson’s disease research.
During its initial phase, the new equipment will
NSLHDNEWS | ISSUE 2 | 11 FEBRUARY 2022
Made with FlippingBook - professional solution for displaying marketing and sales documents online